Intra-Cellular Therapies Inc. buy Cantor Fitzgerald
Start price
14.12.23
/
50%
€59.40
Target price
14.12.24
€91.89
Performance (%)
5.22%
Price
31.05.24
€62.50
Summary
This prediction is currently active. With a performance of 5.22%, the BUY prediction by Cantor_Fitzgerald for Intra-Cellular Therapies Inc. is trending in the right direction. This prediction currently runs until 14.12.24. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Intra-Cellular Therapies Inc. | 3.306% | 3.306% |
iShares Core DAX® | -0.552% | 3.281% |
iShares Nasdaq 100 | -1.415% | 4.535% |
iShares Nikkei 225® | -0.877% | -1.739% |
iShares S&P 500 | -0.415% | 3.239% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Intra-Cellular Therapies Inc. diskutieren
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $101.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Stopped prediction by Cantor_Fitzgerald for Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€68.50
24.04.24
24.04.24
€112.30
24.04.25
24.04.25
-8.76%
31.05.24
31.05.24
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€64.80
23.02.24
23.02.24
€93.28
23.02.25
23.02.25
-3.55%
31.05.24
31.05.24
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€51.30
03.11.23
03.11.23
€94.07
03.11.24
03.11.24
17.93%
31.05.24
31.05.24
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€52.40
29.03.23
29.03.23
€80.23
29.03.24
29.03.24
22.14%
30.03.24
30.03.24